Morgan Stanley Reports 18.5% Revenue Growth and EPS Beat, Target Raised to $202

MSMS

On October 15th, Morgan Stanley posted Q3 EPS of $2.80, beating consensus by $0.73, and revenue rose 18.5% YoY to $17.98 billion. Keefe, Bruyette & Woods raised its price target from $184 to $202 and Wolfe Research upgraded to outperform, while CEO Edward Pick sold 100,000 shares at $164.34.

1. Institutional Investors Increase Positions

During the third quarter, Diversified Trust Co boosted its holdings in Morgan Stanley by 63.9%, acquiring an additional 18,800 shares to reach a total of 48,243 shares valued at $7.67 million. Vanguard Group Inc. modestly increased its stake by 1.1% in the prior quarter, adding 1.35 million shares to hold 119.12 million shares worth $16.78 billion. Fisher Asset Management lifted its position by 3.2%, growing to 24.05 million shares valued at $3.39 billion, while Norges Bank initiated a new position valued at $2.23 billion. Collectively, institutional investors now control 84.19% of the company’s outstanding shares, underscoring broad confidence among large fiduciaries.

2. Strong Q3 Earnings and Rising Dividend

In its latest quarterly report, Morgan Stanley delivered earnings per share of $2.80, surpassing consensus estimates by $0.73 and representing a 48.9% increase from the prior year’s $1.88. Revenue climbed 18.5% year-over-year to $17.98 billion, outpacing analysts’ forecasts by $1.56 billion. Return on equity stood at 16.4%, while net margin reached 13.85%. The firm declared a $1.00 per share dividend for the quarter, maintaining a payout ratio of 41.03% and translating into a 2.2% annualized yield based on the current share count.

3. Analyst Upgrades Signal Momentum

Several research houses have revised their outlook on Morgan Stanley in recent months. Keefe, Bruyette & Woods raised their target from $184 to $202 and assigned an outperform rating, while Wolfe Research elevated the stock from peer perform to outperform with a $198 target. UBS Group and JPMorgan Chase & Co. both adjusted their targets higher and maintained neutral stances, reflecting growing optimism about the firm’s revenue mix and capital market positioning. Overall, three analysts rate the stock as Strong Buy, eight as Buy and seven as Hold, yielding a consensus view of Moderate Buy.

Sources

DZ